tirzepatide updates today FDA Says Compounded Must Exit the Market 💉 WEEK 1 UPDATE 💉,

R., Turik, M., Lalonde, R

"Triple-Hormone-Receptor Agonist Retatrutide for Obesity." NEJM 2023;389:514526 FDA Prescription Drug User Fee Act (PDUFA) Guidelines FDA Center for Drug Evaluation and Research (CDER): NDA review process ClinicalTrials.gov: TRIUMPH Phase 3 program trial registry Historical obesity drug approval precedents: Semaglutide, Tirzepatide, Liraglutide Frequently Asked Questions Based on the current timeline, retatrutide FDA approval is expected in late 2027 to Q1 2028

However, due to its extended half-life, CJC-1295 provides a more prolonged and stable GH release, leading to consistent levels of IGF-1 without the need for daily administration

Lowenstein et al

Your podcast really helped me see the bigger picture

some maintain most weight loss with strong lifestyle habits